Literature DB >> 30761610

Cystic fibrosis - an example of personalized and precision medicine.

Marianne Skov1, Christine Rønne Hansen2, Tacjana Pressler3.   

Abstract

Cystic fibrosis (CF) is a severe, monogenic, autosomal recessive disease caused by mutations in the CFTR (cystic fibrosis transmembrane regulator) gene, where disturbed chloride and bicarbonate transportation in epithelial cells results in a multiorgan disease with primarily pulmonary infections and pancreatic insufficiency. In 1968, the Copenhagen CF Center was established, and centralized care of CF patients with monthly control was introduced. Close monitoring and treatment of Pseudomonas lung infection as well as segregation of patients with different infection status improved the clinical outcome as well as survival. Prophylactic basic treatment as well as infection treatments follow specific algorithms. A variety of comorbidities have all along the pulmonary infection control necessitated personalized care, adjusted to the patients' phenotype. With the introduction of CFTR modulators, the treatment has shifted from prophylactic, symptomatic type toward a new era of precision medicine targeting the basic defect according to the patients' CFTR genotype. Future directions will focus on further improvement of the CFTR modulators and gene therapy, as well as modifier genes and CF phenotype.
© 2019 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CFTR modulators; Pseudomonas; cystic fibrosis; personalized medicine; precise medicine

Mesh:

Substances:

Year:  2019        PMID: 30761610     DOI: 10.1111/apm.12915

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

Review 1.  CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Authors:  Garima Sharma; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

2.  Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.

Authors:  Neeraj Vij
Journal:  J Pers Med       Date:  2021-02-03

3.  Hearing the Voice of a Shadow Child: Healthy Siblings Experience of Cystic Fibrosis and Other Life-Threatening Conditions.

Authors:  Andrew Cox; Colin Pritchard
Journal:  J Patient Exp       Date:  2020-08-14

4.  Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers.

Authors:  Bernardo Cabral; Vito Terlizzi; Onofrio Laselva; Carlos Conte Filho; Fabio Mota
Journal:  J Clin Med       Date:  2022-02-26       Impact factor: 4.241

5.  Increased sputum lactate during oral glucose tolerance test in cystic fibrosis.

Authors:  Peter Østrup Jensen; Bibi Uhre Nielsen; Mette Kolpen; Tacjana Pressler; Daniel Faurholt-Jepsen; Inger Hee Mabuza Mathiesen
Journal:  APMIS       Date:  2022-05-30       Impact factor: 3.428

6.  Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids.

Authors:  Iris A L Silva; Violeta Railean; Aires Duarte; Margarida D Amaral
Journal:  J Pers Med       Date:  2021-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.